Calidi Biotherapeutics has replaced its existing lease with a new 44-month lease for its offices and lab space, starting in October 2026. The company expects this move will save roughly $1.1 million per year in rent and facility costs. The lease includes a three-year renewal option.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding CALIDI BIOTHERAPEUTICS INC (CLDI)?

Major stakeholders currently include Armistice Capital, LLC ($209.9K), Sabby Management, LLC ($103.9K), Warberg Asset Management LLC ($59.5K). Based on the latest 13F filings, there are a total of 28 tracked investment funds and institutions maintaining positions in CLDI.

What is the overall institutional sentiment toward CLDI recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $45.9K, driven by 12 managers accumulating shares while 8 reduced their exposure.

Which institutions have been selling or reducing their CLDI positions?

In the latest period, 3 funds trimmed their holdings, and 5 managers completely exited their positions. The aggregate reported sell value was $234.5K.

Are there any notable investors adding CLDI to their portfolios?

Yes, buying activity remains notable. 5 institutions opened new positions in {ticker}, and 7 existing holders added to their shares. The total reported buy value for the quarter amounted to $437.4K.